DelistingMay 22, 2026, 04:22 PM
Transcode Therapeutics Receives Nasdaq Delisting Notice
AI Summary
Transcode Therapeutics, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum stockholders' equity requirement. The company's reported stockholders' equity of $1,251,427 is below the required $2,500,000. Transcode Therapeutics has until July 3, 2026, to submit a plan to regain compliance, with a potential 180-day extension. Failure to comply could result in the delisting of its common stock, which would materially adversely affect the company.
Key Highlights
- Transcode Therapeutics received a Nasdaq deficiency letter on May 19, 2026.
- The company is not in compliance with Nasdaq Listing Rule 5550(b)(1) requiring $2,500,000 minimum stockholders' equity.
- Transcode Therapeutics reported stockholders' equity of $1,251,427 as of March 31, 2026.
- The company has 45 calendar days, until July 3, 2026, to submit a plan to regain compliance.
- Nasdaq may grant an extension of up to 180 calendar days to regain compliance.
- Failure to regain compliance could lead to delisting from the Nasdaq Capital Market.
- Delisting would have a material adverse effect on the company and its share value.
Price Impact
More from RNAZ